ADAP - Adaptimmune Therapeutics plc
| Previous Close | 5.36 |
| Open | 5.27 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1200 |
| Day's Range | 5.10 - 5.39 |
| 52 Week Range | 4.82 - 14.62 |
| Volume | 371,966 |
| Avg. Volume | 609,325 |
| Market Cap | 539.581M |
| Beta (3Y Monthly) | 2.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.91 |
| Earnings Date | Mar 13, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.43 |
- GlobeNewswire•5 days ago
Adaptimmune Announces that Gwen Binder will leave in January 2019
PHILADELPHIA and OXFORD, United Kingdom, Dec. 12, 2018 -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief.
- GlobeNewswire•19 days ago
Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•27 days ago
Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT
Q3 2018 Adaptimmune Therapeutics PLC Earnings Call
Market Realist•last monthuniQure Stock Rose 35.7% Yesterday—Here’s Why
On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.
- Simply Wall St.•last month
What You Must Know About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) Financial Strength
Adaptimmune Therapeutics plc (NASDAQ:ADAP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is ADAP Read More...
- GlobeNewswire•last month
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells.
- GlobeNewswire•2 months ago
Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial.
- Motley Fool•2 months ago
3 Beaten-Down Biotech Stocks: Can They Bounce Back?
See if these oncology-driven drugmakers have what it takes to recover from recent setbacks.
- Zacks•2 months ago
Adaptimmune Therapeutics Worldwide Enters Oversold Territory
Adaptimmune Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- MarketWatch•2 months ago
Adaptimmune's stock tumbles after cancer study results prompts price target cut
Shares of Adaptimmune Therapeutics PLC slumped 21% in morning trade Monday, after the results from a trial of its cancer treatment prompted Raymond James to slash its price target. The biopharmaceutical company said over the weekend that it was encouraged by the safety data from ongoing studies of SPEAR T-cells, but said no patients were treated in a Cohort 2 "triple tumor" study because the Safety Review Committee recommended an escalated dose. Raymond James analyst Reni Benjamin cut his target to $16 from $20, as the true efficacy of the product may only be determined at the higher, 5-billion-cell dose level. "Although still early, we believe higher doses will likely need to be evaluated with a larger population," Benjamin wrote in a note to clients. "We are decreasing our probability of success from 35% to 25% as we await a stronger correlation between dose, persistence, and clinical response." The stock has slumped 19% over the past three months but was still up 27% year to date, while the S&P 500 has slipped 1.2% the past three months and has gained 3.6% this year.
- GlobeNewswire•2 months ago
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
PHILADELPHIA and OXFORD, United Kingdom, Oct. 08, 2018 -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today.
- Barrons.com•3 months ago
3 Biotech Stocks That Big Investors Are Snatching Up
In the last two weeks, large investors have paid more than $51 million to buy more stock in three biotech firms.
- Simply Wall St.•3 months ago
Should You Be Holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) Right Now?
If you’re interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
Market Realist•4 months agoAdaptimmune Therapeutics Rose 21% in Week Ended August 24
On August 24, Adaptimmune Therapeutics (ADAP) stock closed at $10.25, which represents a ~21% growth from its previous week’s closing price of $8.48 on August 17.
- Zacks•4 months ago
Options Traders Expect Huge Moves in Adaptimmune (ADAP) Stock
Adaptimmune (ADAP) needs investors to pay close attention to the stock based on moves in the options market lately.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of ADAP earnings conference call or presentation 2-Aug-18 12:00pm GMT
Q2 2018 Adaptimmune Therapeutics PLC Earnings Call
- ACCESSWIRE•5 months ago
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Adaptimmune Therapeutics PLC Sponsored ADR (NASDAQ: ADAP ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 ...
